SEC Form 4 · accession 0001349929-17-000085
CANCER GENETICS, INC · CGIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Pappajohn
Director · 10% Owner
Period of report
Sep 28, 2017
Accepted (ET)
Oct 2, 2017 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001349929
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1 | Sep 28, 2017 | A | 2,500 | $0.00 | A | 2,631,204 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.75 | Sep 28, 2017 | A | 5,000 | A | Sep 28, 2018 | Sep 28, 2027 | Common Stock, par value $0.0001 per share | 5,000 | 5,000 | D |
Explanation of responses
- F1The restricted stock underlying the award vests in two equal installments on September 28, 2018 and September 28, 2019, respectively.
- F2The option vests in two equal installments on September 28, 2018 and September 28, 2019, respectively.